Disease management
They will provide the first access to an AI-enabled minimal residual disease test in India.
The tech giant also announced a new atrial fibrillation history feature and sleep stage tracking.
If patients reported severe or worsening symptoms, their care teams were alerted.
The AI platform can predict a person's risk of having a stroke or a heart attack in the next five years.
The AI system can also classify abnormal tissues as malignant or benign.
The telemedicine platform will start by offering diabetes care support.
The companies said their long-term goal is to develop and offer more digital health tools "through a multi-partner ecosystem" as well as advocate for reimbursement options.
The clearance represents what could be the world's first regulatory approval of a DTx app for hypertension treatment.
Also: Butterfly Network reports a year-over-year revenue increase of more than 25%, with a $44.5 million net loss, and One Medical announces a significant jump in revenue.
Under the deal, MedRhythms would receive a $3 million upfront payment and could earn up to $117.5 million if certain milestones are met.